» Articles » PMID: 29204550

Novel P53 Therapies for Head and Neck Cancer

Overview
Date 2017 Dec 6
PMID 29204550
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human papillomavirus E6 protein. Inactivation of p53 is associated with poor clinical response and outcome; therefore, restoration of the p53 signaling cascade may be an effective approach to ablate HNSCC cells. Viral approaches to restore p53 activity in HNSCC have been well-studied and shown modest activity in clinical trials. Recent work has focused on high-throughput screens and rational designs to identify and develop small molecules to rescue p53 function. Several p53-targeting small molecules have demonstrated very promising activity in pre-clinical studies but have yet progressed to the clinical setting. Further development of p53 therapies, in particular chemical approaches, should be prioritized and evaluated in the HNSCC setting.

Citing Articles

Curcumin: A Potential Weapon in the Prevention and Treatment of Head and Neck Cancer.

Vesela K, Kejik Z, Masarik M, Babula P, Dytrych P, Martasek P ACS Pharmacol Transl Sci. 2024; 7(11):3394-3418.

PMID: 39539276 PMC: 11555516. DOI: 10.1021/acsptsci.4c00518.


Potential Alternative Therapeutic Modalities for Management Head and Neck Squamous Cell Carcinoma: A Review.

Afshari K, Sohal K Cancer Control. 2023; 30:10732748231185003.

PMID: 37328298 PMC: 10278411. DOI: 10.1177/10732748231185003.


p53 Modulates Radiosensitivity in Head and Neck Cancers-From Classic to Future Horizons.

Mirestean C, Iancu R, Iancu D Diagnostics (Basel). 2022; 12(12).

PMID: 36553058 PMC: 9777383. DOI: 10.3390/diagnostics12123052.


Immunoexpression of p53 mutant-type in Iranian patients with primary and recurrence oral squamous cell carcinoma.

Daneste H, Sadeghzadeh A, Mokhtari M, Mohammadkhani H, Lavaee F, Moayedi J Eur J Transl Myol. 2022; 33(1).

PMID: 36413207 PMC: 10141754. DOI: 10.4081/ejtm.2022.10847.


FN1 promotes prognosis and radioresistance in head and neck squamous cell carcinoma: From radioresistant HNSCC cell line to integrated bioinformatics methods.

Tang X, Tang Q, Yang X, Xiao Z, Zhu G, Yang T Front Genet. 2022; 13:1017762.

PMID: 36212151 PMC: 9533212. DOI: 10.3389/fgene.2022.1017762.


References
1.
Sturgis E, Cinciripini P . Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?. Cancer. 2007; 110(7):1429-35. DOI: 10.1002/cncr.22963. View

2.
OMalley Jr B, Chen S, Schwartz M, Woo S . Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 1995; 55(5):1080-5. View

3.
Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E . Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001; 19(2):289-98. DOI: 10.1200/JCO.2001.19.2.289. View

4.
Pirollo K, Hao Z, Rait A, Jang Y, Fee Jr W, Ryan P . p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene. 1997; 14(14):1735-46. DOI: 10.1038/sj.onc.1201116. View

5.
Divya C, Pillai M . Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog. 2006; 45(5):320-32. DOI: 10.1002/mc.20170. View